What Perspective Therapeutics does

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing image-guided targeted alpha-particle therapies (TATs) for cancer. The company's platform centers on the alpha-emitting radioisotope Pb-212, delivered to tumors via proprietary targeting peptides conjugated through a proprietary lead-specific chelator (PSC). A chemically matched Pb-203/212 isotope pair enables theranostics, allowing physicians to confirm target expression via SPECT imaging before administering therapy with the same molecule.

The pipeline includes four clinical-stage candidates. VMT-α-NET targets SSTR2-expressing neuroendocrine tumors and reported 76% of evaluable patients progression-free and alive across Cohorts 1 and 2 with a 39-44% objective response rate in Cohort 2. VMT01 targets MC1R-positive melanoma and is being evaluated both as monotherapy and in combination with nivolumab. PSV359 targets FAP-α-expressing solid tumors, with first patient dosed in April 2025. PSV594 targets CCK2R-expressing solid tumors and remains in candidate evaluation. Supporting platforms include the VMT-α-GEN Pb-212 isotope generator (capacity of 100,000+ doses per year), the CB7-Adma two-step pre-targeting platform licensed from Stony Brook University, and a long-term U.S. Department of Energy supply contract for Th-228 feedstock.

The company operates from Seattle, WA (headquarters), Coralville, IA (discovery research), and Richland, WA (manufacturing), employs 101-250 people, and trades on NYSE American under CATX. Perspective Therapeutics is pre-revenue, with Q1 2026 revenue of approximately $40,000 and a 2025 net loss of $103.1 million. Capital is sourced through equity financings, including a $175 million underwritten offering in February 2026, with cash and short-term investments of $271 million as of March 31, 2026 supporting operations into late 2027. The go-to-market model is enterprise-style, engaging oncologists and nuclear medicine specialists at major cancer centers through multi-center Phase 1/2a clinical trials in pursuit of FDA approval.

Name

Perspective Therapeutics

Legal name

Perspective Therapeutics, Inc.

Website

https://perspectivetherapeutics.com

Company type

Public

Founded year

2023

Operating status

Operating

Headcount range

101–250 employees

Short description

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing Pb-212-based image-guided targeted alpha-particle therapies for neuroendocrine tumors, melanoma, and solid tumors, with four clinical-stage candidates and operations in Seattle, Coralville, and Richland.

Ownership category

akta.pro rank

Product category

Radiopharmaceutical Oncology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industry

Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)

Keywords

• Radiopharmaceutical therapy
• Alpha-particle therapy
• Targeted cancer therapy
• Radiopharmaceutical manufacturing
• Cancer theranostics

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Radiopharmaceutical Cancer Therapies: Pre-revenue clinical-stage company developing targeted alpha-particle radiopharmaceutical therapies for cancer treatment. Revenue will be generated from approved radiopharmaceutical products once clinical trials are completed and regulatory approvals are obtained. The company is advancing three clinical-stage oncology programs with multiple 2026 catalysts expected.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing image-guided targeted alpha-particle therapies (TATs) for cancer treatment using its proprietary Pb-212 alpha-emitting isotope platform combined with high-affinity tumor-targeting peptides and its proprietary Pb-Specific Chelator (PSC). Its pipeline includes four clinical-stage drug candidates addressing neuroendocrine tumors (VMT-α-NET), melanoma (VMT01/02), FAP-α-expressing solid tumors (PSV359), and CCK2R-expressing solid tumors (PSV594), currently in Phase 1/2a trials. The company supports these programs with the VMT-α-GEN isotope generator, a CB7-Adma pre-targeting platform, and a theranostic imaging capability using the Pb-203/Pb-212 matched isotope pair.

Product overview

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing a unified portfolio of image-guided targeted alpha-particle therapies (TATs) for cancer treatment. The company's platform centers on proprietary Pb-212 alpha-emitting isotope technology combined with tumor-specific targeting peptides and a Pb-specific chelator (PSC). Its clinical-stage pipeline includes VMT-α-NET (neuroendocrine tumors), VMT01 (melanoma), and PSV359 (solid tumors), supported by the VMT-α-GEN isotope generator for on-demand Pb-212 production and a pre-targeting platform (CB7-Adma) for enhanced tumor specificity.

Differentiator

Problem solved

Functional benefit

Products and services

• VMT-α-NET Investigational Pb-212 alpha-particle radiopharmaceutical for the diagnosis and treatment of somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors, using Pb-203 SPECT imaging paired with Pb-212 therapy for image-guided patient selection. Currently in Phase 1/2a clinical trials for U.S. oncology and nuclear medicine centers.
• VMT01/02 Investigational Pb-212 alpha-particle radiopharmaceutical for diagnosis and treatment of melanocortin subtype 1 receptor (MC1R)-expressing melanoma, evaluated as monotherapy and in combination with nivolumab. Currently in Phase 1/2a trials for U.S. oncology centers.
• PSV359 Investigational Pb-212 alpha-particle radiopharmaceutical for diagnosis and treatment of Fibroblast Activation Protein-alpha (FAP-α)-expressing solid tumors such as pancreatic, colorectal, lung, and breast cancers. Currently in Phase 1/2a clinical trials.
• PSV594 Investigational Pb-212 alpha-particle radiopharmaceutical candidate targeting cholecystokinin 2 receptor (CCK2R) for diagnosis and treatment of CCK2R-expressing solid tumors. In preclinical development with dosing planned to initiate.

Quantifiable outcome

• 76% of patients remained progression-free and alive across Cohorts 1 & 2 in VMT-α-NET trial
• +4 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• Stony Brook UniversitycoreStrategic or Co-development Partner · 1 February 2024Exclusive worldwide license agreement for CB7-Adma pre-targeting platform technology. Enables development of next-generation two-step targeted alpha therapies using monoclonal antibodies combined with radioligands.
• U.S. Department of Energy Isotope ProgramcoreStrategic or Co-development PartnerLong-term supply contract with National Isotope Development Center of the U.S. Department of Energy Isotope Program for supply of Th-228 feedstock essential for Pb-212 production.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Lantheus Holdings: Lantheus is a leading commercial radiopharmaceutical company (Pylarify, Definity, Point Biopharma assets). It is directly comparable because it is also advancing alpha-emitter programs (via Lantheus Alpha Therapy) and is a strategic investor in Perspective Therapeutics.
• Telix Pharmaceuticals: Telix is a commercial-stage radiopharma company with imaging agents (Illuccix for PSMA imaging) and an emerging therapy pipeline. Directly comparable as a theranostics platform company developing both diagnostic and therapeutic radiopharmaceuticals.
• Fusion Pharmaceuticals: Fusion was a clinical-stage radiopharma developer of targeted alpha therapies using actinium-225 (now part of AstraZeneca). Directly comparable as a pre-commercial alpha-emitter platform peer targeting oncology with proprietary chelator and linker chemistry.
• RayzeBio: RayzeBio was a clinical-stage developer of targeted radiopharmaceutical therapies using actinium-225, acquired by Bristol-Myers Squibb in 2024. Comparable as a Pb/alpha-emitter-adjacent platform peer with similar therapeutic area focus in solid tumors.
• Point Biopharma: Point Biopharma was a clinical-to-commercial radiopharmaceutical developer (now part of Eli Lilly) advancing Lu-177-based therapies. Comparable as a peer radiopharmaceutical platform company that exited via strategic M&A — a reference point for CATX's potential trajectory.
• ITM Isotope Technologies Munich: ITM is a clinical-stage radiopharmaceutical company developing targeted radionuclide therapies (Lu-177 and other isotopes) with in-house isotope production. Comparable as an integrated radiopharma developer combining isotope manufacturing with therapeutic pipeline development.

Broad incumbents

• Novartis (Pluvicto franchise): Novartis commercializes Pluvicto (Lu-177 vipivotide tetraxetan) and Lutathera (Lu-177 dotatate), the dominant approved radioligand therapies. Comparable as the benchmark incumbent in the radioligand therapy space that CATX's alpha-emitter programs must compete against clinically and commercially.
• Bayer (radiopharmaceuticals): Bayer commercializes Xofigo (Ra-223) for prostate cancer bone metastases and has broader radiopharma pipeline interests. Comparable as a large pharmaceutical incumbent with an approved radiopharmaceutical franchise in adjacent oncology indications.

Emerging players

• ARTBIO: ARTBIO is an emerging clinical-stage radiopharma company focused on targeted alpha therapies using lead-212 (Pb-212), directly mirroring CATX's isotope choice. Comparable as the most direct emerging alpha-emitter peer with overlapping technology foundation and indication focus.
• RadioMedix: RadioMedix is a clinical-stage radiopharma company developing diagnostic and therapeutic radiopharmaceuticals including alpha-emitter programs. Comparable as a smaller emerging peer in the same regulatory and clinical environment pursuing theranostic approaches.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Perspective Therapeutics